Regenerative Medical Technology Group Inc.
Regenerative Medical Technology Group Inc.
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series A Preferred Stock | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Series C Preferred Stock | - | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | |||||
Series D Preferred Stock | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Related Party | - | 0 | 0 | -50 | 50 | 0 | 0 | 0 | 0 | 0 | - | |||||
Assets | ||||||||||||||||
Assets Current | ||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Receivables Net Current | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Accounts Receivable Net Current | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | |||||
Inventory Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | |||||
Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets Current | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Other Assets | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Intangible Assets Net Excluding Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Goodwill | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
Assets | 6 | 5 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | |||||
Liabilities And Stockhold… | ||||||||||||||||
Accounts Payable And Accrued Liabilities Current | - | - | - | - | - | - | - | 1 | - | - | - | |||||
Accounts Payable Current | - | - | - | - | - | - | 1 | - | 1 | 0 | 0 | |||||
Liabilities Current | ||||||||||||||||
Interest And Dividends Payable Current | - | - | - | - | - | - | - | 8 | - | - | - | |||||
Accounts Payable And Other Accrued Liabilities Cur… | 0 | 0 | 0 | 0 | 0 | 1 | 1 | - | - | - | - | |||||
Accrued Liabilities Current | 20 | 18 | 17 | 15 | 12 | 11 | 11 | - | 7 | 7 | 7 | |||||
Customer Advances Current | - | - | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Contract With Customer Liability Current | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | |||||
Derivative Liabilities | 3 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Notes Payable Current | - | - | - | - | - | - | - | 17 | 16 | 15 | 17 | |||||
Convertible Notes Payable Current | 2 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | |||||
Notes Payable To Bank Current | 17 | 18 | 17 | 1 | 18 | 18 | 18 | - | - | - | - | |||||
Liabilities Current | 43 | 38 | 37 | 17 | 31 | 30 | 29 | 26 | 24 | 22 | 24 | |||||
Assets Noncurrent | ||||||||||||||||
Convertible Long Term Notes Payable | - | - | - | - | - | - | - | - | - | 0 | - | |||||
Liabilities Noncurrent | ||||||||||||||||
Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | |||||
Long Term Notes Payable | 2 | 2 | 2 | 17 | 3 | 2 | 2 | 0 | - | - | 0 | |||||
Liabilities | 45 | 41 | 39 | 35 | 34 | 32 | 31 | 29 | 27 | 25 | 25 | |||||
Stockholders Deficit | ||||||||||||||||
Stockholders Equity | ||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 40 | 41 | 41 | 44 | 41 | 40 | 40 | 40 | 40 | 40 | 40 | |||||
Retained Earnings Accumulated Deficit | -79 | -76 | -75 | -74 | -70 | -68 | -68 | -66 | -64 | -62 | -62 | |||||
Stockholders Equity | -39 | -36 | -35 | -30 | -29 | -28 | -27 | -26 | -24 | -22 | -22 | |||||
Liabilities And Stockholders Equity | 6 | 5 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 6,500 | 100 | 100 | 6,500 | |||||
Common Stock Shares Issued | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 12 | 12 | 12 | 14 | |||||
Shares Outstanding | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 12 | 12 | 12 | 14 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -45.00% | 74.88% | - | - | - | - | - | - | - | - | - | - |
| 2025 | -42.43% | -24.09% | -18.34% | 15.80% | -13.90% | -2.90% | -33.33% | -36.00% | -34.67% | -3.52% | -37.57% | 98.50% |
| 2024 | 16.67% | 13.89% | 100.83% | -45.52% | -45.00% | -26.20% | - | - | - | -4.04% | -35.86% | -11.62% |
| 2023 | - | - | - | - | - | - | -31.65% | -34.18% | 271.31% | 24.72% | 11.11% | 18.03% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | ||||||||||||||||
| Current Ratio | 0.05 | 0.04 | 0.03 | 0.09 | 0.06 | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | 0.05 | |||||
| Quick Ratio | 0.03 | 0.03 | 0.03 | 0.08 | 0.05 | 0.04 | 0.04 | 0.02 | 0.03 | 0.02 | 0.05 | |||||
| Working Capital | -40.33M | -36.64M | -35.60M | -15.76M | -28.63M | -28.43M | -27.72M | -25.73M | -23.69M | -21.67M | -23.24M | |||||
Leverage & Debt | ||||||||||||||||
| Debt to Equity | -1.15 | -1.14 | -1.13 | -1.15 | -1.15 | -1.14 | -1.14 | -1.12 | -1.13 | -1.13 | -1.15 | |||||
| Interest Coverage TTM | 0.00 | -0.09 | -0.12 | -0.10 | -0.09 | -0.04 | -0.15 | -1.73 | -4.45 | - | - | |||||
| Debt Ratio | 7.71 | 8.11 | 8.74 | 7.65 | 7.47 | 8.06 | 8.16 | 9.47 | 8.72 | 8.57 | 7.50 | |||||
Efficiency & Turnover | ||||||||||||||||
| Asset Turnover TTM | 1.82 | 1.42 | 1.23 | 0.93 | 0.83 | 0.87 | 0.62 | 0.54 | 0.44 | 0.44 | 0.41 | |||||
| Days Sales Outstanding TTM | 2.85 | 1.46 | 2.38 | 7.15 | 4.66 | 2.47 | 4.72 | 4.79 | 10.94 | 5.58 | 5.41 | |||||
| Receivables Turnover TTM | 128.16 | 249.39 | 153.58 | 51.06 | 78.35 | 147.77 | 77.27 | 76.15 | 33.37 | 65.38 | 67.43 | |||||
Per Share Metrics | ||||||||||||||||
| Diluted EPS TTM | -0.71 | -0.60 | -0.62 | -0.52 | -0.34 | -0.38 | -0.34 | -0.81 | -0.81 | -0.79 | -0.85 | |||||
| Free Cash Flow Per Share TTM | -0.07 | -0.12 | -0.10 | -0.08 | -0.04 | 0.01 | -0.02 | -0.02 | -0.06 | -0.06 | -0.05 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | ||||||||||||||||
| Gross Profit Margin TTM | 59.76% | 56.99% | 55.11% | - | - | - | - | 68.96% | 69.97% | 69.53% | 67.77% | |||||
| Operating Profit Margin TTM | 0.46% | -12.11% | -17.00% | -15.90% | -10.48% | -6.19% | -14.33% | -11.11% | -4.31% | 0.00% | 0.00% | |||||
| Net Profit Margin TTM | -99.74% | -124.36% | -153.18% | -185.86% | -136.27% | -161.28% | -192.89% | -353.35% | -413.98% | -407.21% | -446.91% | |||||
Growth Metrics | ||||||||||||||||
| Net Revenue Growth (1Y) | 199.74% | 114.32% | 129.13% | 22.82% | 28.69% | 23.43% | -5.71% | 38.01% | 20.97% | 57.49% | 94.04% | |||||
| Net Income Growth (1Y) | 119.39% | 65.26% | 81.95% | -35.40% | -57.64% | -51.11% | -59.30% | 68.14% | 83.71% | 78.21% | 73.38% | |||||
| EPS Growth (1Y) | 108.02% | 57.71% | 80.47% | -35.63% | -57.79% | -51.47% | -59.59% | 67.46% | 82.98% | 74.95% | 67.64% | |||||
Valuation Metrics | ||||||||||||||||
| P/E TTM | -0.06 | -0.05 | -0.08 | -0.12 | -0.13 | -0.08 | -0.08 | -0.04 | -0.05 | -0.01 | -0.02 | |||||
| P/B TTM | -0.02 | -0.01 | -0.02 | -0.03 | -0.02 | -0.01 | -0.01 | -0.02 | -0.02 | -0.00 | -0.01 | |||||
| P/S TTM | 0.06 | 0.06 | 0.12 | 0.22 | 0.17 | 0.13 | 0.16 | 0.15 | 0.21 | 0.04 | 0.07 | |||||
| Market Cap | 608.34K | 361.32K | 619.08K | 789.95K | 539.18K | 401.25K | 357.15K | 437.29K | 512.25K | 90.86K | 160.53K | |||||
| Enterprise Value | 3.43M | 1.35M | 1.71M | 16.59M | 1.73M | 1.22M | 1.23M | 17.13M | 16.18M | 14.82M | 15.99M | |||||
Calculated Values | ||||||||||||||||
| Free Cash Flow TTM | -966.32K | -1.58M | -1.31M | -1.03M | -560.35K | 143.66K | -226.85K | -308.10K | -757.27K | -804.80K | -609.35K | |||||
| Net Debt | 2.82M | 986.00K | 1.09M | 15.80M | 1.19M | 820.21K | 877.32K | 16.69M | 15.66M | 14.73M | 15.83M | |||||
Per-Share and Margin | ||||||||||||||||
| EPS TTM | ||||||||||||||||
| Adjusted EPS TTM | ||||||||||||||||
| Cash Flow Per Share TTM | ||||||||||||||||
| Pretax Margin TTM | ||||||||||||||||
| Stock Comp to Revenue TTM | ||||||||||||||||
Turnover Ratios and Averages | ||||||||||||||||
| Average Assets | ||||||||||||||||
| Average Equity | ||||||||||||||||
| Average Inventory | ||||||||||||||||
| Average Receivables | ||||||||||||||||
| Average Accounts Payables | ||||||||||||||||
| Inventory Turnover TTM | ||||||||||||||||
| Payables Turnover TTM | ||||||||||||||||
| Days Inventory Outstanding TTM | ||||||||||||||||
| Days Payables Outstanding TTM | ||||||||||||||||
| Cash Conversion Cycle TTM | ||||||||||||||||
| Working Capital to Revenue | ||||||||||||||||
| Deferred Revenue to Revenue | ||||||||||||||||
Growth Rates | ||||||||||||||||
| Total Assets Growth (1Y) | ||||||||||||||||
| Total Assets Growth (3Y) | ||||||||||||||||
| Total Assets Growth (5Y) | ||||||||||||||||
| Dividends Paid Growth (1Y) | ||||||||||||||||
| Dividends Paid Growth (3Y) | ||||||||||||||||
| Dividends Paid Growth (5Y) | ||||||||||||||||
| EPS Growth (3Y) | ||||||||||||||||
| EPS Growth (5Y) | ||||||||||||||||
| Net Income Growth (3Y) | ||||||||||||||||
| Net Income Growth (5Y) | ||||||||||||||||
| Net Profit Margin Growth (1Y) | ||||||||||||||||
| Net Profit Margin Growth (3Y) | ||||||||||||||||
| Net Profit Margin Growth (5Y) | ||||||||||||||||
| Net Revenue Growth (3Y) | ||||||||||||||||
| Net Revenue Growth (5Y) | ||||||||||||||||
| Deferred Revenue Growth (1Y) | ||||||||||||||||
| Retained Earnings Growth (1Y) | ||||||||||||||||
Credit, Liquidity, Returns, Payout | ||||||||||||||||
| Cash Ratio | ||||||||||||||||
| Net Working Capital | ||||||||||||||||
| Debt to EBITDA TTM | ||||||||||||||||
| Net Debt to EBITDA TTM | ||||||||||||||||
| Net Debt to Equity | ||||||||||||||||
| Altman A | ||||||||||||||||
| Altman B | ||||||||||||||||
| Altman C | ||||||||||||||||
| Altman D | ||||||||||||||||
| Altman E | ||||||||||||||||
| Altman Z-Score | ||||||||||||||||
| ROA TTM | ||||||||||||||||
| ROE TTM | ||||||||||||||||
| NOPAT TTM | ||||||||||||||||
| ROIC TTM | ||||||||||||||||
| Effective Tax Rate TTM | ||||||||||||||||
| Payout Ratio TTM | ||||||||||||||||
| Dilution Ratio | ||||||||||||||||
| Retained Earnings to Equity | ||||||||||||||||
| Treasury Stock to Equity | ||||||||||||||||
| Treasury Stock Change (1Y) | ||||||||||||||||
| Accrued to Current Liabilities | ||||||||||||||||
| NCAV | ||||||||||||||||
| NCAV Per Share TTM | ||||||||||||||||
Valuation Ratios | ||||||||||||||||
| P/CF TTM | ||||||||||||||||
| PEG Ratio | ||||||||||||||||
| Dividend Yield TTM | ||||||||||||||||
| Free Cash Flow Yield TTM | ||||||||||||||||
| EV EBITDA TTM | ||||||||||||||||
| EV EBIT TTM | ||||||||||||||||
| EV Revenue TTM | ||||||||||||||||
| EV FCF TTM | ||||||||||||||||
| Stock Compensation TTM | ||||||||||||||||
| Adjusted Net Income TTM | ||||||||||||||||
| Billings TTM | ||||||||||||||||
| Total Debt | ||||||||||||||||
| Invested Capital | ||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Regenerative Medical Technology Group Inc. (RMTG) — SEC Financial Statements & Analysis
Regenerative Medical Technology Group Inc. (RMTG) is a retail-retail stores, nec company. Regenerative Medical Technology Group Inc. trades on OTC as: RMTG. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Regenerative Medical Technology Group Inc. reported a 199.74% year-over-year revenue growth, a Gross Profit Margin of 59.76% (TTM), a Debt-to-Equity ratio of -1.15x, a Price-to-Sales (P/S) ratio of 0.06x (TTM), a Price-to-Book (P/B) ratio of -0.02x (TTM), at a market cap of $608.34K. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 199.74%
- Gross Profit Margin TTM
- 59.76%
- Debt To Equity
- -1.15x
- P/S TTM
- 0.06x
- P/B TTM
- -0.02x
- Market Cap
- $608.34K
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Regenerative Medical Technology Group Inc. in?
Regenerative Medical Technology Group Inc. (RMTG) operates in the Retail-Retail Stores, NEC industry.
What is RMTG's market cap?
Regenerative Medical Technology Group Inc. (RMTG) has a market capitalization of $608.34K as of 2026-06-30.
What exchange does RMTG trade on?
Regenerative Medical Technology Group Inc. (RMTG) trades on the OTC.